Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy.

BACKGROUND: The Combined Aerobic and Resistance Exercise Trial tested different types and doses of exercise in breast cancer patients receiving chemotherapy. Here, we explore potential moderators of the exercise training responses.
METHODS: Breast cancer patients initiating chemotherapy (N=301) were randomly assigned to three times a week, supervised exercise of a standard dose of 25-30 min of aerobic exercise, a higher dose of 50-60 min of aerobic exercise, or a higher dose of 50-60 min of combined aerobic and resistance exercise. Outcomes were patient-reported symptoms and health-related fitness. Moderators were baseline demographic, exercise/fitness, and cancer variables.
RESULTS: Body mass index moderated the effects of the exercise interventions on bodily pain (P for interaction=0.038), endocrine symptoms (P for interaction=0.029), taxane/neuropathy symptoms (P for interaction=0.013), aerobic fitness (P for interaction=0.041), muscular strength (P for interaction=0.007), and fat mass (P for interaction=0.005). In general, healthy weight patients responded better to the higher-dose exercise interventions than overweight/obese patients. Menopausal status, age, and baseline fitness moderated the effects on patient-reported symptoms. Premenopausal, younger, and fitter patients achieved greater benefits from the higher-dose exercise interventions.
CONCLUSIONS: Healthy weight, fitter, and premenopausal/younger breast cancer patients receiving chemotherapy are more likely to benefit from higher-dose exercise interventions.

RCT Entities:   Population Interventions Outcomes

Aerobic and resistance exercise improve physical functioning and manage some symptoms in cancer patients (Mishra ) and survivors (Mishra ). Few exercise trials, however, have compared different types or doses of exercise in cancer patients to identify the optimal exercise prescription for a given outcome (Schmitz ). Moreover, few exercise trials have formally tested moderators to identify which cancer patients may respond best to a particular exercise intervention (Courneya , 2009). Such information is critical for understanding what type and dose of exercise might be optimal for improving a particular outcome in a given subset of cancer patients. Here, we report the largest trial to date to examine moderators of the exercise response in cancer patients and the first to examine moderators of different types and doses of exercise.

The Combined Aerobic and Resistance Exercise (CARE) Trial compared a three times per week standard dose of 25–30 min of aerobic exercise (STAN) to a higher dose of 50–60 min of aerobic exercise (HIGH) and a higher dose of 50–60 min of combined aerobic and resistance exercise (COMB) in breast cancer patients receiving chemotherapy. We previously reported several positive effects of the higher-dose interventions compared with STAN for physical functioning, endocrine symptoms, bodily pain, and health-related fitness (Courneya ). In secondary papers, we also reported that the higher-dose interventions were superior to STAN for managing sleep quality (Courneya ) and depression in patients with clinical levels of depressive symptoms (Courneya ). In this report, we examined clinical moderators of the main outcomes of the CARE trial to determine whether selected subgroups of breast cancer patients responded better or worse to the higher-dose exercise interventions. We included not only several standard demographic and exercise/fitness variables but also key cancer variables that make the field of exercise oncology unique (Courneya, 2014). On the basis of previous results from the CARE Trial (Courneya , 2014c), we hypothesised that higher physical functioning breast cancer patients (e.g., healthy weight, fitter, younger, previous exercisers, and more tolerable treatments) would respond better to the higher-dose exercise interventions compared with lower physical functioning patients.

Materials and Methods

Setting and participants

The CARE Trial methods have been reported previously (Courneya ). The CARE Trial was a multicentre trial with sites in Edmonton, Ottawa, and Vancouver, Canada. Ethics approval was received for each centre and each patient provided informed consent. Eligibility criteria were women ⩾18 years old with stage I–IIIc breast cancer initiating adjuvant chemotherapy. Women were excluded if they had transabdominal rectus abdominis muscle reconstructive surgery, incomplete axillary surgery, another significant health problem, or were not approved by their treating oncologist. Eligible participants were identified by their treating oncologist in the clinic and recruited by a research coordinator.

Randomisation

After baseline assessments, participants were stratified by centre and chemotherapy regimen (any Herceptin vs no Herceptin/any taxane vs no Herceptin/no taxane) and randomly assigned to STAN, COMB, or HIGH in a 1 : 1 : 1 ratio using a computer-generated program. The allocation sequence was generated in Edmonton and concealed from the project directors at each site who assigned participants to groups.

Exercise training interventions

Details of the exercise training interventions have been described elsewhere (Courneya ). Briefly, participants exercised for the duration of their chemotherapy treatment. STAN were prescribed the Physical Activity Guidelines for Americans (United States Department of Health and Human Services, 2008), which have been endorsed for cancer survivors (Schmitz ; Rock ). The guidelines recommend a minimum of 75 min of vigorous intensity aerobic exercise spread over at least 3 days per week (i.e., 25–30 min per session). HIGH followed double the minimum guidelines of 150 min of vigorous intensity aerobic exercise per week (i.e., 50–60 min per session). COMB followed the same aerobic exercise guideline as STAN plus a resistance training programme for 3 days per week that was completed immediately after the aerobic exercise portion (i.e., about 50–60 min of total combined exercise). For each supervised exercise session, exercise trainers recorded the attendance and completion of the exercise prescription.

Selection and assessment of outcomes for the moderator analyses

We examined the main patient-reported outcomes and health-related fitness outcomes from the CARE Trial (Courneya ). Patient-reported outcomes were assessed at baseline, twice during chemotherapy, and 3–4 weeks after chemotherapy and consisted of physical functioning and bodily pain assessed by the Medical Outcomes Survey Short Form (SF)-36 (Ware ); as well as fatigue symptoms (Yellen ), taxane/neuropathy symptoms (Cella ), and endocrine symptoms (Fallowfield ).

Health-related fitness outcomes were assessed at baseline and post chemotherapy. Aerobic fitness was evaluated using a maximal incremental exercise protocol on a treadmill (Wasserman ). Muscular strength was determined by an equation that used 7–10 repetitions of a submaximal weight to estimate maximal strength on the leg press and horizontal bench press (Kraemer ). Whole-body fat mass and lean body mass were assessed by dual energy X-ray absorptiometry.

Selection and assessment of moderators

We selected 12 moderators on the basis of their scientific plausibility, clinical utility, distribution in our data set, and support in previous research (Courneya , 2009, 2014a, 2014c). Three moderators were demographic variables consisting of age (<50 years vs ⩾50 years), marital status (married vs not married), and menopausal status (premenopausal vs postmenopausal). Four moderators were exercise/fitness variables consisting of meeting aerobic exercise guidelines at baseline (equivalent of <150 vs ⩾150 min of exercise per week), meeting strength exercise guidelines at baseline (aerobic fitness (<27.5 vs ⩾27.5 ml kg−1 min−1), and body mass index (<25.0 vs 25.0–29.9 vs ⩾30 kg m−2). Five moderators were cancer variables consisting of disease stage (stages I/IIa vs stages IIb/III), type of surgery (lumpectomy vs mastectomy), anthracycline treatment (no vs yes), taxane treatment (none vs concurrent vs sequential), and length of chemotherapy (12 weeks vs ⩾18 weeks).

Data analyses

We used repeated-measures analyses of covariance to assess effect modification of the interventions by each hypothesised moderator in the form of an interaction test. We modelled each of the five patient-reported outcomes at the three post-randomisation time points to compare the average mean change over time across intervention–moderator groups (Diggle ). We used univariate analyses of covariance for each of the four health-related fitness outcomes that had only one post-randomisation time point. For muscular strength, we report only the upper body strength measure as the interaction results were the same as for the lower body strength measure. Consistent with our main analyses (Courneya ), we adjusted for the baseline value of the outcome, age, education, previous exercise, body mass index, disease stage, surgery type, and chemotherapy protocol. For all analyses, we followed the intention-to-treat principle and included all participants with follow-up data. We examined demographic moderators only for patient-reported outcomes because there was limited biologic plausibility for their effect on objective exercise responses. We conducted 96 tests of interactions but did not adjust for multiple comparisons because our trial was not powered to detect interactions and we considered these analyses to be hypothesis generating. Moreover, our approach was to interpret the general pattern of the results rather than any isolated interactions.

Results

Participant flow through the trial has been reported elsewhere (Courneya ). Briefly, we randomised 301 of 728 (41%) eligible patients and obtained complete patient-reported outcome data on 296 (98.3%) patients. The distribution of the proposed moderators is reported in Table 1. Detailed adherence to the exercise interventions is reported elsewhere (Courneya ). STAN, HIGH, and COMB attended 88%, 82%, and 78% of their aerobic exercise sessions (P=0.004) with an average duration of 28 (s.d.=4), 48 (s.d.=8), and 27 (s.d.=3) min, respectively. COMB completed 66% (33/50) of the strength training sessions.

Table 1

Baseline distribution of proposed moderators in the CARE Trial, Canada, 2008–2011

Variables	Overall (n=296)	Standard (n=95)	High (n=99)	Combined (n=102)
Demographic variables
Age
<50 years	148 (50.0%)	50 (52.6%)	55 (55.6%)	43 (42.2%)
⩾50 years	148 (50.0%)	45 (47.4%)	44 (44.4%)	59 (57.8%)
Marital status
Married	192 (64.9%)	59 (62.1%)	63 (63.6%)	70 (68.6%)
Not Married	104 (35.1%)	36 (37.9%)	36 (36.4%)	32 (31.4%)
Menopausal status
Premenopausal	182 (61.5%)	64 (67.4%)	63 (63.6%)	55 (53.9%)
Postmenopausal	114 (38.5%)	31 (32.6%)	36 (36.4%)	47 (46.1%)
Exercise/fitness variables
Baseline aerobic exercise
Not meeting guidelines	207 (69.9%)	66 (69.5%)	71 (71.7%)	70 (68.6%)
Meeting guidelines	89 (31.1%)	29 (30.5%)	28 (28.3%)	32 (31.4%)
Baseline strength exercise
Not meeting guidelines	234 (79.1%)	75 (78.9%)	81 (81.8%)	78 (76.5%)
Meeting guidelines	62 (20.9%)	20 (21.1%)	18 (18.2%)	24 (23.5%)
Baseline aerobic fitness
<27.5 ml kg−1 min−1	145 (49.0%)	43 (45.3%)	43 (43.4%)	59 (57.8%)
⩾27.5 ml kg−1 min−1	151 (51.0%)	52 (54.7%)	56 (56.6%)	43 (42.2%)
Body mass index
Healthy weight	146 (49.3%)	46 (48.4%)	58 (58.6%)	42 (41.2%)
Overweight	81 (27.4%)	33 (34.7%)	26 (26.3%)	22 (21.6%)
Obese	69 (23.3%)	16 (16.8%)	15 (15.2%)	38 (37.3%)
Cancer variables
Disease stage
I/IIa	203 (68.6%)	62 (65.3%)	70 (70.7%)	71 (69.6%)
IIb/IIIa	93 (31.4%)	33 (34.7%)	29 (29.3%)	31 (30.4%)
Surgical protocol
Lumpectomy	167 (56.4%)	47 (49.5%)	57 (57.6%)	63 (61.8%)
Mastectomy	129 (43.6%)	48 (50.5%)	42 (42.4%)	39 (38.2%)
Anthracycline treatment
No anthracyclines	214 (72.3%)	62 (65.3%)	74 (74.7%)	78 (76.5%)
Anthracyclines	82 (27.7%)	33 (34.7%)	25 (25.3%)	24 (23.5%)
Taxane treatment
No taxane	28 (9.5%)	7 (7.4%)	11 (11.1%)	10 (9.8%)
Concurrent taxane	115 (38.9%)	40 (42.1%)	36 (36.4%)	39 (38.2%)
Sequential taxane	153 (51.7%)	48 (50.5%)	52 (52.5%)	53 (52.0%)
Length of chemotherapy
12 weeks	89 (31.1%)	28 (29.5%)	28 (28.3%)	33 (32.4%)
⩾18 weeks	207 (69.9%)	67 (70.5%)	71 (71.7%)	69 (67.6%)

Abbreviation: CARE=Combined Aerobic and Resistance Exercise.

Values are represented as n (%).

Statistically significant interactions were identified for 13 of the 96 (14%) tests. Note that for many of the outcomes, including aerobic fitness, there was a substantial decline over the course of chemotherapy and the benefit of the higher-dose exercise interventions was to partially blunt these declines. Body mass index moderated the effect of the exercise interventions on bodily pain (P for interaction=0.038; Figure 1a), endocrine symptoms (P for interaction=0.029; Figure 1b), taxane/neuropathy symptoms (P for interaction=0.013; Figure 1c), aerobic fitness (P for interaction=0.041; Figure 1d), muscular strength (P for interaction=0.007; Figure 1e), and fat mass (P for interaction=0.005; Figure 1g). Stratified subgroup analyses (Table 2) generally showed that healthy weight patients benefited from the higher-dose exercise interventions more than overweight/obese patients with one exception; obese patients benefitted more from the COMB intervention for fat mass than healthy/overweight patients.

Figure 1

Body mass index as a moderator of exercise effects during breast cancer chemotherapy on ( Note: positive change scores (or less negative change scores) are better for all outcomes except fat mass. Abbreviations: COMB=combined aerobic and resistance exercise; HIGH=high volume of aerobic exercise; STAN=standard volume of aerobic exercise.

Table 2

Stratified subgroup analyses for significant interactions based on body mass index

	HIGH vs STAN		COMB vs STAN		HIGH vs COMB
	M (95% CI)	P	M (95% CI)	P	M (95% CI)	P
Bodily pain
Healthy weight (n=146)	+3.6 (+1.0 to +6.1)	0.006	+2.6 (−0.1 to +5.3)	0.059	+1.0 (−1.5 to +3.5)	0.44
Overweight/obese (n=150)	+0.2 (−2.7 to +3.1)	0.88	−2.1 (−4.7 to +0.6)	0.12	+2.3 (−0.4 to +5.0)	0.097
Endocrine symptoms
Healthy weight (n=146)	+4.2 (+1.7 to +6.7)	0.001	+5.5 (−0.1 to +5.3)	<0.001	−1.3 (−3.8 to +1.2)	0.32
Overweight/obese (n=150)	−0.4 (−3.5 to +2.8)	0.81	+0.3 (−2.5 to +3.2)	0.82	−0.7 (−3.6 to +2.2)	0.63
Taxane symptoms
Healthy weight (n=146)	+3.8 (+1.6 to +5.9)	0.001	+1.7 (−0.6 to +4.1)	0.14	+2.0 (−0.2 to +4.2)	0.069
Overweight/obese (n=150)	−2.1 (−5.3 to +1.0)	0.18	−1.0 (−3.9 to +1.9)	0.48	−1.1 (−4.1 to +1.9)	0.46
Aerobic fitness (ml kg−1 min−1)
Healthy weight (n=143)	+1.7 (+0.1 to +3.2)	0.032	+1.0 (−0.7 to +2.7)	0.26	+0.7 (−0.9 to +2.3)	0.38
Overweight/obese (n=135)	−0.4 (−1.7 to +0.9)	0.56	−1.3 (−2.5 to −0.2)	0.026	+1.0 (−0.3 to +2.2)	0.12
Muscular strength (kg)
Healthy weight (n=143)	−2.5 (−4.4 to −0.6)	0.010	+5.3 (+3.2 to +7.4)	<0.001	−7.8 (−9.7 to −5.9)	<0.001
Overweight/obese (n=135)	−0.3 (−2.7 to +3.1)	0.80	+2.8 (+0.7 to +4.9)	0.008	−3.1 (−5.3 to −0.9)	0.006
Fat mass (kg)
Healthy/overweight (n=223)	−0.4 (−1.2 to +0.4)	0.28	+0.2 (−0.7 to +1.0)	0.70	−0.6 (−1.4 to +0.2)	0.14
Obese (n=66)	+1.3 (−1.6 to +4.2)	0.38	−1.5 (−4.0 to +1.0)	0.23	+2.8 (+0.4 to +5.2)	0.024

Abbreviations: CI=confidence interval; COMB=combined aerobic and resistance exercise; HIGH=high volume of aerobic exercise; M=mean; STAN=standard volume of aerobic exercise.

Between-group differences in mean change are adjusted for baseline value of the outcome, age, education, baseline exercise, body mass index, disease stage, surgery type, and chemotherapy protocol.

Menopausal status moderated the effect of the exercise interventions on bodily pain (P for interaction=0.015; Figure 2a), endocrine symptoms (P for interaction=0.039; Figure 2b), and taxane/neuropathy symptoms (P for interaction=0.016; Figure 2c). Age moderated the effect of the exercise interventions on bodily pain (P for interaction=0.023; Figure 2d) and taxane/neuropathy symptoms (P for interaction=0.045; Figure 2e). Stratified subgroup analyses (Table 3) generally showed that premenopausal and younger patients responded better to the HIGH intervention compared with postmenopausal and older patients. Finally, baseline aerobic fitness moderated the effect of the exercise interventions on endocrine symptoms (P for interaction=0.001; Figure 2f) and taxane/neuropathy symptoms (P for interaction=0.041; Figure 2g). Stratified subgroup analyses (Table 3) showed that fitter patients benefited more from both the higher-dose exercise interventions, whereas less fit patients showed no benefit.

Figure 2

Menopausal status as a moderator of exercise effects during breast cancer chemotherapy on ( Note: positive change scores (or less negative change scores) are better for all outcomes. Abbreviations: COMB=combined aerobic and resistance exercise; HIGH=high volume of aerobic exercise; STAN=standard volume of aerobic exercise.

Table 3

Stratified subgroup analyses for significant interactions based on menopausal status, age, and baseline aerobic fitness

	HIGH vs STAN		COMB vs STAN		HIGH vs COMB
	M (95% CI)	P	M (95% CI)	P	M (95% CI)	P
Bodily pain by menopause
Premenopausal (n=182)	+3.9 (+1.7 to +6.2)	0.001	+0.3 (−2.0 to +2.7)	0.78	+3.6 (+1.2 to +6.0)	0.003
Postmenopausal (n=114)	−0.6 (−3.9 to +2.7)	0.72	−0.3 (−3.2 to +2.7)	0.85	−0.3 (−3.2 to +2.5)	0.82
Endocrine symptoms by menopause
Premenopausal (n=182)	+3.8 (+1.2 to +6.4)	0.004	+4.3 (+1.5 to +7.0)	0.003	−0.5 (+1.2 to +6.0)	0.74
Postmenopausal (n=114)	−0.2 (−3.1 to +2.6)	0.87	+0.8 (−1.8 to +3.4)	0.54	−1.0 (−3.5 to +1.5)	0.42
Taxane symptoms by menopause
Premenopausal (n=182)	+3.0 (+0.8 to +5.3)	0.008	+1.5 (−0.8 to +3.9)	0.20	+1.5 (−0.9 to +3.9)	0.21
Postmenopausal (n=114)	−1.5 (−4.9 to +1.8)	0.37	−0.8 (−3.8 to +2.2)	0.60	−0.7 (−3.7 to +2.2)	0.62
Bodily pain by age
<50 years (n=148)	+4.4 (+2.0 to +6.9)	<0.001	+0.5 (−2.2 to +3.1)	0.72	+4.0 (+1.4 to +6.6)	0.003
⩾50 years (n=148)	−0.0 (−3.0 to +2.9)	0.98	−0.0 (−2.6 to +2.6)	0.99	−0.0 (−2.7 to +2.6)	0.98
Taxane symptoms by age
<50 years (n=148)	+3.4 (+1.0 to +5.7)	0.005	+1.8 (−0.7 to +4.4)	0.16	+1.6 (−1.0 to +4.1)	0.22
⩾50 years (n=148)	−0.4 (−3.4 to +2.6)	0.80	−0.2 (−2.9 to +2.5)	0.88	−0.2 (−2.9 to +2.5)	0.90
Endocrine symptoms by aerobic fitness
<27.5 ml kg−1 min−1 (n=145)	−1.1 (−3.9 to +1.7)	0.44	−0.2 (−2.9 to +2.4)	0.86	−0.9 (−3.5 to +1.8)	0.51
⩾27.5 ml kg−1 min−1 (n=151)	+5.3 (+2.6 to +8.0)	<0.001	+5.9 (+3.1 to +8.8)	<0.001	−0.6 (−3.4 to +2.1)	0.65
Taxane symptoms by aerobic fitness
<27.5 ml kg−1 min−1 (n=145)	−0.7 (−3.8 to +2.4)	0.65	−1.3 (−4.2 to +1.7)	0.39	+0.6 (−2.4 to +3.5)	0.70
⩾27.5 ml kg−1 min−1 (n=151)	+3.1 (+1.0 to +5.3)	0.005	+3.1 (+0.7 to +5.4)	0.010	+0.1 (−2.2 to +2.3)	0.95

Abbreviations: CI=confidence interval; COMB=combined aerobic and resistance exercise; HIGH=high volume of aerobic exercise; M=mean; STAN=standard volume of aerobic exercise.

Between-group differences in mean change are adjusted for baseline value of the outcome, age, education, baseline exercise, body mass index, disease stage, surgery type, and chemotherapy protocol.

No significant interactions were observed for the moderators of marital status, disease stage, type of surgery, anthracycline treatment, taxane treatment, length of chemotherapy, or meeting either exercise guideline at baseline. Moreover, no significant interactions were observed for the outcomes of patient-reported physical functioning, fatigue, or lean body mass.

Discussion

To our knowledge, the CARE Trial is the largest exercise trial to date to examine moderators of the exercise response in cancer patients, and the first to examine moderators of different types and doses of exercise. The most consistent moderator of the exercise response in the CARE Trial was body mass index. As hypothesised, the general pattern of findings was that healthy weight patients experienced greater benefit from the higher-dose interventions than overweight/obese patients. In the Healthy Exercise for Lymphoma Patients (HELP) Trial, we observed that healthy weight and obese (but not overweight) patients achieved a better response to aerobic exercise for patient-reported physical functioning (Courneya ) and that obese patients achieved a better response for sleep quality (Courneya ). Conversely, a study of endometrial cancer survivors reported no differences in response to an unsupervised exercise programme based on body mass index; however, that study did not have a comparison group (Basen-Engquist ). One possible explanation for our finding is that the overweight/obese patients had worse adherence to the higher-dose exercise interventions (about 65%) compared with the standard dose intervention (about 80%) (Courneya ). Another possible explanation is that the additional symptom burden experienced by obese breast cancer patients may blunt the response to the higher-dose exercise interventions (Schmitz ).

Obesity is a growing issue in cancer care with obese cancer patients experiencing more treatment complications and poorer outcomes than healthy weight patients (Schmitz ). Our data suggest minimal benefit from higher-dose exercise interventions compared with a standard exercise dose for overweight/obese breast cancer patients receiving chemotherapy. Interestingly, the one benefit that favoured obese patients was fat loss from the COMB intervention. Previous trials have reported that combined exercise produces more fat loss than aerobic or resistance exercise alone even when controlling for exercise volume (Church ; Ho ). This fat loss from COMB in obese breast cancer patients receiving chemotherapy may have important implications for reducing recurrence and early mortality (Schmitz ). Exercise type and dose trials specifically targeting body composition in obese breast cancer patients may be warranted.

Two of the other identified moderators, menopausal status and age, are closely linked. These variables moderated the exercise response for bodily pain, endocrine symptoms, and taxane/neuropathy symptoms. Stratified subgroup analyses showed that premenopausal and younger patients responded to the HIGH intervention, whereas postmenopausal and older patients showed no additional benefits. Differences in adherence do not appear to explain these findings (Courneya ). In the Supervised Trial of Aerobic vs Resistance Training (START), we found that younger breast cancer patients receiving chemotherapy experienced a better aerobic fitness response than older patients (Courneya ). Conversely, age did not predict the exercise response of prostate cancer patients receiving radiation therapy (Alberga ). Age is associated with greater functional decline and more cancer treatment complications that may impede the ability to benefit from higher-dose exercise compared with standard doses (Courneya ). It is also possible that premenopausal/younger breast cancer patients benefit more because they are forced into early menopause from the chemotherapy treatments and experience more symptoms (Loprinzi ).

Interestingly, none of the ‘cancer variables' moderated the effects of exercise on the main outcomes. We previously reported in the CARE Trial that the type of surgery moderated the effects of exercise on sleep quality (Courneya ) and that taxane treatment moderated the effects on depression (Courneya ). Moreover, in START, we found that taxane treatment moderated the effects of weight training on muscular strength gains; and disease stage moderated the effects on body composition changes (Courneya ). Other studies have also reported that cancer variables moderate the exercise response of lymphoma patients (Courneya , 2012) and breast cancer patients (Segal ) but not prostate cancer patients (Segal ). It is possible that cancer variables moderate the effects of exercise interventions differently depending on the type of cancer, the types of treatments, and whether exercise is compared with no exercise or with different types and doses of exercise. Cancer variables should continue to be explored as moderators of the exercise response because they are fundamental to the field of exercise oncology (Courneya, 2014).

We also found no significant interactions for marital status despite reporting such interactions in two previous trials (Courneya , 2009). In the START (Courneya ) and HELP Trials (Courneya ), unmarried breast cancer and lymphoma patients experienced a greater quality of life benefit than married patients from a supervised exercise programme compared with no exercise. In the CARE Trial, all three groups received a supervised exercise intervention with similar social interaction and support, thereby negating any social support benefit from a supervised exercise intervention. Again, these data suggest that moderators of the exercise response may vary when comparing exercise to no exercise vs different types and doses of exercise.

We also found no significant interactions involving self-reported baseline exercise. This finding is interesting because self-reported exercise is often used as an exclusion criterion with the assumption that cancer patients already meeting guidelines are less likely to benefit from an exercise intervention. Few trials, however, have actually tested this assumption. In fact, in previous reports from the CARE Trial, we actually observed that patients meeting the aerobic exercise guidelines were more likely to benefit from the HIGH intervention in terms of sleep quality (Courneya ), and patients meeting the strength exercise guidelines were more likely to benefit from the COMB intervention in terms of sleep quality (Courneya ) and depression (Courneya ). These data suggest that the effects of self-reported baseline exercise on the exercise response of cancer patients receiving chemotherapy may be complex and should be examined in future trials.

The overall strengths of our trial have been noted elsewhere (Courneya ) and include being the largest exercise trial in breast cancer patients receiving chemotherapy, the first to compare exercise dose and type effects, multicentre recruitment, good adherence rates, intention-to-treat analysis, and trivial loss-to-follow-up. Additional strengths of the present report include the clinical utility of our selected moderators, our inclusion of several novel cancer variables as moderators, and the direct tests of interactions. The overall limitations of our trial have also been noted elsewhere (Courneya ) and include the modest recruitment rate and the lower adherence rates among the higher-dose exercise groups. Additional limitations of the present report include our limited statistical power to detect interactions and the 96 interaction tests that would likely result in 5 false discoveries if all tests were null. Nevertheless, the 13 significant interactions we identified showed a consistent pattern of moderators (i.e., body mass index, age, menopausal status, and fitness) and outcomes (i.e., bodily pain, endocrine symptoms, and taxane/neuropathy symptoms) that suggest a low likelihood of chance findings.

It is also important to note that the CARE Trial manipulated only one component of exercise dose and tested only one approach for combining aerobic and resistance exercise. In the CARE Trial, the HIGH group performed double the duration of a vigorous intensity aerobic exercise intervention that was performed 3 days per week. We did not manipulate the intensity, frequency, or periodisation of aerobic exercise and, therefore, cannot speak to the effects or subgroup effects of such manipulations in breast cancer patients receiving chemotherapy. Moreover, the COMB group performed the resistance exercise immediately after the aerobic exercise and, therefore, we cannot speak to the effects or subgroup effects of a combined exercise programme where the aerobic and resistance exercise are performed on separate days or where the resistance exercise is performed before the aerobic exercise.

In summary, our moderator analyses of the main outcomes of the CARE Trial showed a general pattern in which slimmer, fitter, and younger/premenopausal breast cancer patients receiving chemotherapy were more likely to benefit from the higher-dose exercise interventions than their counterparts. These results reinforce the idea that exercise prescriptions in cancer patients should be individualised, taking into account age, menopausal status, obesity, past exercise experience, initial fitness level, and treatment protocol. In terms of dissemination, these higher-dose exercise interventions could be implemented at other cancer centres and community-based fitness centres with appropriate facilities and qualified staff. Given their level of sophistication and required motivation, it is unclear whether these exercise programmes could be self-directed by breast cancer patients receiving chemotherapy. Additional research manipulating other aspects of the exercise prescription including frequency, intensity, periodisation, and sequencing are needed to determine the optimal exercise programme for breast cancer patients receiving chemotherapy. Moreover, identifying which cancer patients respond best to which type, volume, intensity, and sequencing of exercise interventions will further inform clinical practice and improve outcomes for breast cancer patients.